Business
IGC Pharma Expands CALMA Phase 2 Trial with Site at Lynn Health Science Institute in Oklahoma City
POTOMAC, MD / ACCESS Newswire / August 25, 2025 / IGC Pharma, Inc. (NYSE American:IGC) today announced the expansion of its ongoing Phase 2 clinical trial evaluating IGC-AD1, an investigational drug candidate for treating agitation in patients with ...
About this update from Igc Pharma, Inc.
[{"type":"text","content":"POTOMAC, MD / ACCESS Newswire / August 25, 2025 / IGC Pharma, Inc. (NYSE American:IGC) today announced the expansion of its ongoing Phase 2 clinical trial evaluating IGC-AD1, an investigational drug candidate for treating agitation in patients with Alzheimer's disease. The Company has added a clinical site at the Lynn Health Science Institute (LHSI) in Oklahoma City, Oklahoma.","length":383,"tagName":"p"},{"type":"text","content":"Dr. Carl Griffin, MD, will serve as the Principal Investigator for the site. Dr. Griffin brings extensive experience in conducting clinical trials and a deep commitment to improving outcomes for patients affected by neurodegenerative diseases. He and the team at LHSI will begin recruiting eligible patients immediately.","length":320,"tagName":"p"},{"type":"text","content":""Expanding our clinical footprint to Oklahoma represents another important step toward reaching more patients and families affected by this devastating condition," said Ram Mukunda, CEO of IGC Pharma. "We are pleased to welcome Dr. Griffin and the Lynn Health Science Institute to the CALMA trial and look forward to their contributions in advancing our mission."","length":383,"tagName":"p"},{"type":"text","content":"The CALMA trial is a randomized, double-blind, placebo-controlled Phase 2 study designed to evaluate the safety and efficacy of IGC-AD1 in reducing agitation in individuals diagnosed with Alzheimer's disease. Agitation is one of the most challenging and disruptive symptoms associated with Alzheimer's, often leading to earlier institutionalization and significant caregiver stress.","length":390,"tagName":"p"},{"type":"text","content":"Lynn Health Science Institute is now actively enrolling participants. For more information, please contact:","length":107,"tagName":"p"},{"type":"text","content":"Mikayla DadeClinical Research Coordinator - Lynn Health Science InstituteEmail: [email protected]: (405) 602-3939 ext. 106","length":128,"tagName":"p"},{"type":"text","content":"To learn more about IGC Pharma and the CALMA trial, please visit www.igcpharma.com.","length":83,"tagName":"p"},{"type":"text","content":"About Lynn Health Science Institute OKC","length":39,"tagName":"p"},{"type":"text","content":"Lynn Health Science Institute (LHSI), located in Oklahoma City, Oklahoma, is a premier clinica...